The kit measures concentration of exogenous cel-miR-39-3p spiked in RNA isolates
Assay format is 96 wells
Standard is synthetic miRNA-based
Components of the kit are provided ready to use, concentrated or dried
Research topic
Exogenous control, Spike-in control
Summary
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
Concentration of target miRNA measured by miREIA can be affected by efficiency of RNA isolation. Therefore, it is recommended to normalize the measured concentration of target miRNA to the efficiency of RNA isolation using an exogenous control.
Efficiency of RNA isolation can be monitored by adding a defined amount of synthetic non-human miRNA, e.g. cel-miR-39-3p miRNA, to the sample during RNA isolation. The synthetic RNA is processed the same way as the target RNA present in the samples.
After RNA isolation, concentration of exogenous cel-miR-39-3p added to the samples is measured by cel-miR-39-3p miREIA in parallel with the concentration of the target miRNA. To calculate the coefficient of isolation efficiency, the amount of cel-miR-39-3p added to the samples prior to isolation is divided by the concentration of cel-miR-39-3p measured by miREIA.
Finally, the concentration of target miRNA measured by miREIA is multiplied by the coefficient of isolation efficiency for every sample.
If such a normalization is applied, then, each RNA isolate sample is measured by two miREIA kits: one kit for determination of the target miRNA (samples are diluted as recommended in the corresponding datasheet) and by a second kit, cel-miR-39-3p miREIA (samples are diluted 10-fold as written in page 15).
